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Background: Chronic cerebral hypoperfusion causes damage to brain’s white matter  underpinning 
vascular cognitive impairment. Inflammation and oxidative stress have been proposed as key 
pathophysiological mechanisms of which the transcription factor Nrf2 is a master  regulator. We 
hypothesised that white matter pathology, microgliosis, blood brain barrier breakdown  and behavioural 
deficits induced by chronic hypoperfusion would be exacerbated in mice deficient in the transcription 
factor Nrf2.  
Methods: Mice deficient in Nrf2 (male heterozygote or homozygous for Nrf2 knockout) or wild type 
littermates on a C57Bl6/J background underwent bilateral carotid artery stenosis (BCAS) to induce 
chronic cerebral hypoperfusion or sham surgery and survived for a further 6 weeks. White matter 
pathology was assessed with MAG immunohistochemistry as a marker of altered axon-glial integrity; 
alterations to astrocytes and microglia/macrophages were assessed with GFAP and Iba1 
immunohistochemistry and blood brain barrier breakdown was assessed with IgG 
immunohistochemistry.  Behavioural alterations were assessed using 8-arm radial arm maze and 
alterations to Nrf2-related and inflammatory-related genes were assessed with qRT-PCR.  
Results: Chronic cerebral hypoperfusion induced white matter pathology, elevated 
microglial/macrophage levels and blood brain barrier breakdown in white matter tracts that were 
increased in Nrf2+/- mice and further exacerbated by the complete absence Nrf2. Chronic hypoperfusion 
induced white matter astrogliosis and induced an impairment in behaviour assessed with radial arm 
maze, however, these measures were not affected by Nrf2 deficiency. Although Nrf2-related antioxidant 
gene expression was not altered by chronic cerebral hypoperfusion, there was evidence for elevated pro-
inflammatory related gene expression following chronic hypoperfusion that was not affected by Nrf2 
deficiency. 
Conclusions: The results demonstrate that the absence of Nrf2 exacerbates white matter pathology and 
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Sustained cerebral hypoperfusion is one of the pathophysiological mechanisms contributing to cognitive 
decline in ageing,  vascular cognitive impairment (VCI)  and Alzheimer’s Disease (AD) by causing 
damage to brain’s white matter [1-3]. White matter hyperintensities (WMH) are frequently detected in 
ageing, AD and VCI, and MRI and neuropathological investigation suggests they can be attributed to 
cerebral hypoperfusion [3, 4]. Furthermore, the burden of WMH has been correlated with a decline in 
global cognitive performance, executive function and processing speed [5, 6] The severity of 
hypoperfusion predicts conversion from mild cognitive impairment to dementia [7, 8]. 
 
Animal models of chronic cerebral hypoperfusion have provided evidence for a causal link between 
cerebral hypoperfusion, white matter pathology and cognitive deficits (reviewed in [1]). We 
demonstrated that bilateral carotid artery stenosis (BCAS) in mice causes chronic cerebral 
hypoperfusion  [9], white matter alterations detected using diffusion-tensor MRI [10], and impaired 
axon-glial integrity [11, 12]. Furthermore, we showed that the white matter disruption caused by BCAS 
induces a selective deficit in spatial working memory [11], reminiscent of the disrupted frontal cortical 
circuitry found in VCI, that progresses to encompass spatial reference memory deficits in the longer 
term response [13].  
 
An elevated inflammatory response and oxidative stress are implicated in the pathogenesis of white 
matter damage following cerebral hypoperfusion. Elevated levels of microglia/macrophages parallel 
white matter damage after chronic cerebral hypoperfusion, and correlate with impaired white matter 
function and cognitive deficits [9, 11, 14-16].  At a mechanistic level, activated microglia may damage 
white matter after chronic hypoperfusion by sustained elevation of pro-inflammatory molecules such as 
TNFα, IL-1β, IL-6, MCP-1 and complement pathways [16-18]. Genetic and pharmacological inhibition 
of complement pathways can reduce activated microglia and attenuate white matter pathology and 
cognitive deficits [16] induced by cerebral hypoperfusion. Similarly, other broad-spectrum anti-
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inflammatory approaches can reduce white matter pathology, protect white function and cognitive 
deficits in models of cerebral hypoperfusion [14, 19]. Inflammation causes oxidative stress which is also 
proposed to contribute mechanistically to white matter damage and can in turn exacerbate inflammation 
[20, 21].  Markers of oxidative damage to proteins, lipid and nucleic acids and increased levels of free 
radicals have been reported in models of chronic hypoperfusion [22-25].  Oxidative stress induced by 
chronic hypoperfusion may be mediated by decreased levels of antioxidant enzymes such as SOD, 
catalase and glutathione, through mitochondrial dysfunction or indirectly via free radical production 
from increased levels of inflammatory cells [26-28]. 
 
The transcription factor nuclear factor erythroid 2-related factor (Nrf2) is a master regulator of 
endogenous cytoprotective anti-oxidant and anti-inflammatory signalling pathways [29]. Our work and 
that of others have demonstrated that cerebral hypoperfusion can activate Nrf2 signalling [30-32]. 
Consistent with a mechanistic role for inflammation and oxidative stress in causing white matter damage 
after chronic hypoperfusion, boosting Nrf2 signalling has protective effects in models of chronic 
cerebral hypoperfusion. Pharmacological approaches to activate Nrf2 signalling, including dimethyl 
fumarate and sulforaphane protect white matter function and cognitive deficits induced by cerebral 
hypoperfusion [15, 33]. Furthermore, other protective approaches in models of cerebral hypoperfusion, 
such as environment enrichment and olfactory ensheathing cell transplantation are reported to act by 
activating Nrf2 signalling [34, 35]. We reported a role for astrocytic Nrf2 in protecting white matter and 
behavioural deficits following chronic cerebral hypoperfusion in mice [36], these protective effects were 
paralleled by attenuated astrogliosis and pro-inflammatory gene expression. 
 
Conversely, lack of Nrf2 has been shown to exacerbate pathology and functional outcome in other 
models of neurodegenerative diseases that, in common with chronic hypoperfusion, feature oxidative 
stress and inflammation as disease mechanisms. These include models of Parkinson’s Disease[37], 
familial amyotrophic lateral sclerosis  [38] and AD [39-42].  In models of white matter disease (sciatic 
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nerve injury and EAE), lack of Nrf2 impairs re-myelination and functional recovery [43, 44] indicating 
that Nrf2 is involved in maintaining white matter during pathological conditions, and promoting white 
matter repair. Furthermore, Nrf2 has been shown to play a role in maintaining white matter structural 
integrity under normal physiological conditions, as Nrf2 knock out mice display age-related white matter 
disruption [45]. Collectively, these studies suggest that Nrf2 plays a role regulating white matter in 
health and disease. However, it is presently unclear if Nrf2 knockout mice are more vulnerable to the 
pathology and cognitive deficits following chronic cerebral hypoperfusion. Therefore, in the present 
study, we hypothesised that in mice deficient in Nrf2, white matter pathology and behavioural deficits 


























All experiments were conducted in accordance with the Animal (Scientific Procedures) Act 1986 
and local ethical approval at the University of Edinburgh, and were performed under personal and 
project licences granted by the UK Home Office according to ARRIVE guidelines. Nrf2 knockout 
mice were originally developed by Chan et al 1996 [46]. The Nrf2 gene was knocked out in 
embryonic stem cells (129X1SvJ) by homologous recombination. Adult male and female Nrf2 
knockout mice (homozygous and heterozygous for Nrf2 knockout) were obtained from the Jackson 
Laboratory (strain B6.129X1-Nfe2l2tm1Ywk/J stock number 017009; backcrossed onto C57Bl/6 mice 
for at least 10 generations).  Imported male and female homozygous Nrf2-/- mice were bred with each 
other whereas Nrf2+/- were bred with wild type C57Bl/6Jax mice. First generation mice from both 
Nrf2-/+ and Nrf2-/- breeding pairs were used for experiments. In accordance with information 
available from Jackson (https://www.jax.org/strain/017009), Nrf2-/- were poor breeders and limited 
numbers of male Nrf2-/- were produced, therefore a mix of Nrf2+/- and Nrf2-/-  mice were used for 
experiments. Mice were initially group housed on a 12-hour light/dark cycle with ad libitum access 
to food and water, and assigned experimental groups by genotype then randomly assigned surgery; 
wild type sham (n = 7), wild type hypoperfused (n = 10), Nrf2+/- sham (n = 7), Nrf2+/- hypoperfused 
(n = 7), Nrf2-/- sham (n=3), Nrf2-/- hypoperfused (n=3) . All mice were male, mean age 6 months (25-
44g).  Three animals tolerated surgery poorly and had to be culled (2 wild type hypoperfused, 1 
Nrf2+/- hypoperfused. Experimenters were blind to genotype and surgery status of the mice 
throughout data collection and analysis. 
 
Bilateral Carotid Artery Stenosis  
Bilateral carotid artery stenosis (BCAS) surgery was carried out as previously described [11]. All 
surgical procedures were conducted using aseptic techniques while under isoflurane anaesthesia (5% 
induction, 1.5% maintenance), In brief, a small cervical midline incision was made, and the common 
8 
 
carotid arteries were exposed.  A 0.18 mm internal diameter microcoil (Sawane Spring Co, Japan. 
Fig 2.1b) was placed around one common carotid artery, the animal was allowed to recover and was 
30 min later re-anesthetised for the placement of the second microcoil (0.18 mm). Sham surgery was 
performed in the same manner excluding the placement of the microcoils.  
 
8-arm radial arm maze to assess behavioural alterations  
Behavioural testing commenced four weeks post-BCAS. Animals were singly housed and food 
restricted (maintained at 85% of initial body weight) one week prior to, and throughout the radial 
arm maze test to promote motivation (12-hour light/dark cycle, ad libitum access to water).  
Following the last trial animals were again provided food ad libitum. 
The radial arm maze comprises a central platform (20 cm in diameter) surrounded by 8 arms (47 cm 
long by 7 cm wide with 20 cm Plexiglas walls). Each arm has a 2-cm deep plastic well for placement of 
a sugar pellet and all arms can be isolated from the central platform by Plexiglas doors (remotely 
controlled using Any-Maze software, Stoelting, UK). Large visual cues were placed on each of the four 
walls surrounding the maze, and a camera mounted on the ceiling was used for data acquisition (Any-
Maze software, Stoelting, UK). 
Pre-training consisted of one 5 min trial of free exploration with sugar pellets scattered at random, and 
one where each animal was allowed to walk down each arm from the central platform to retrieve sugar 
pellets from the plastic cups.  The training was carried out for 16 consecutive days (1 trial/day). Each 
arm was baited with a sugar pellet and the animal was placed in the central platform at the start of the 
trial. The animal was confined to the central platform for 5 seconds between each arm choice and the 
trial finished when the animal had retrieved all 8 pellets or when 25 minutes had elapsed. The number 
of revisiting errors (visits into unbaited arms) during each trial were recorded and analysed as a measure 
of behaviour. 
Nrf2+/- and Nrf2-/- were grouped together for radial arm maze analysis. Animals that explored less than 
75% of the maze during 2 of the first 4 trials were excluded from analysis due to lack of motivation 
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resulting in skewed learning profile. Two animals were excluded according to this criterion (one wild 
type BCAS and one Nrf2 -/- sham). Therefore final group sizes for behavioural analysis were wild type 
sham (n=7), wild type BCAS (n=7), Nrf2 deficient sham (Nrf2+/- n=7, Nrf2-/- n=2), Nrf2 deficient BCAS 
(Nrf2+/- n=6, Nrf2-/- n=3). 
 
Immunohistochemistry 
Six weeks after the onset of BCAS, mice were culled under deep anaesthesia by transcardiac 
perfusion and hemi brains were snap frozen in liquid nitrogen for qPCR, or post-fixed in 4% 
paraformaldehyde for 24 hours, placed in 30% sucrose for 72 hours, then frozen in isopentane at -
42°C for 2 minutes. Coronal sections (30μm) were cut using a cryostat and stored in cyroprotective 
medium at -20°C. Sections were washed in PBS (3 x 15 mins), TB (2 x 15 mins) then mounted onto 
superfrost slides (VWR International) and air dried then dehydrated through a series of alcohols 
(70%, 90%, 100%) then placed in xylene for 10 minutes. Sections were then placed in 100% ethanol 
and endogenous peroxidases were quenched in 3% hydrogen peroxide in methanol. Antigen retrieval 
was undertaken for Iba1 and GFAP immunohistochemistry, sections were incubated in 10mM citric 
acid buffer (pH 6.0) at 95°C for 10 minutes. Sections were blocked with 10% normal serum and 
0.5% bovine albumin serum before overnight incubation with primary antibody at 4°C. Following 
block, immunoglobulin G (IgG) immunostained sections were incubated overnight  with horse anti-
mouse IgG antibody (Vector Labs BA-2000; 1:2500). Primary antibodies and concentrations were 
as follows: Anti-myelin associated glycoprotein (MAG; Abcam ab89780 1:15000; Anti-glial 
fibrillary acidic protein (GFAP; Life technologies 13-0300 1:1000); Anti Ionised calcium binding 
adaptor molecule-1 (Iba-1; Menarini MP290-CR05 1:1000). The appropriate biotinylated secondary 
antibody (Vector Labs) were incubated for 1 hour at room temperature and then further amplified by 
incubating with Vector ABC solution before visualisation of peroxidase activity using 
3.3’diaminobenzidine tetrahydrochloride (DAB, Vector Labs, UK). IgG immunostained sections were 
counterstained with haematoxylin to aid region of interest analysis. Sections were then dehydrated 
through a series of alcohols, placed in xylene then coverslips mounted. Images were acquired using a 
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BX51 microscope (Olympus, UK) or a Zeiss Axio Scope.A1 (Zeiss, UK). Images were analysed for 
percentage area of MAG, Iba1, GFAP and IgG  as described in the corpus callosum, internal capsule 
and optic tract which were manually delineated by the experimenter. Briefly, ImageJ software (v1.46, 
NIH, Bethesda, MD, USA) was used to apply a global manual threshold followed by quantification of 
the positive signal detected above the selected threshold. IgG immunostained sections underwent colour 
deconvolution in Image J (H&E DAB) to remove blue counterstained nuclei and the RenyiEntropy 
threshold was applied.  Occasionally, animals were excluded from analysis as the anatomical area was 
missing from the slide (1 wild type BCAS and 1 Nrf2+/- animal omitted from Iba1 analyses of internal 
capsule and optic tract; 1 wild type BCAS animal omitted from GFAP internal capsule analysis).  
 
RNA extraction, reverse transcription-PCR and quantitative (q)-PCR  
RNA was isolated from optic tract-enriched samples dissected from snap-frozen hemibrains.  RNA was 
extracted using the QIAGEN RNeasy Lipid Tissue Mini Kit according to manufacturer’s instruction. 
Briefly, <100mg fresh frozen tissue was homogenised in 1ml QIAzol® lysis reagent using the Qiagen 
automated tissue lyser system and metal beads. The homogenate was transferred to fresh Rnase/Dnase 
free tubes and incubated for 2 minutes at room temperature with 200µl chloroform. The upper aqueous 
phase was collected following 15 min centrifugation at 4°C (12,000 x g), and RNA was subsequently 
purified in mini spin columns and washed with a series of buffers before it was eluted in Rnase free 
water. Rnase-free Dnase I (Thermo Scientific/QIAGEN) was used to remove genomic DNA according 
to manufacturer’s instruction. cDNA was synthesised from 1-3 µg RNA using the Roche Transcriptor 
First Strand cDNA Synthesis Kit, according to manufacturer’s instruction. Briefly, RNA was added to 
reverse transcriptase reaction mix and cycled through 10 min 25°C; 30 min 55°C; 5 min 85°C. No RT 
control was run alongside and cDNA was diluted to the equivalent of 3 ng initial RNA per 15 µl qPCR 
reaction. The CFX96 Real-Time PCR Machine (Bio Rad) was used with the DyNAmo ColorFlash 
SYBR Green qPCR kit according to manufacturer’s instructions (Thermo Scientific). cDNA template 
was mixed with SYBR green master mix, water and forward and reverse primer (200 nM each final 
concentration). Samples were run in duplicates alongside no template and no RT negative controls. 
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Primers were validated to confirm efficiency prior to use and sequences used are as follows: Gapdh-F 
5’-GGGTGTAACCACGAGAAAT-3’ Gapdh-R 5’-CCTTCCACAATGCCAAAGTT-3’ Nrf2-F 5’-
CAGCTCAAGGGCACAGTGC-3’ Nrf2-R 5’-GTGGCCCAAGTCTTGCTCC-3’ Slc7a11-F 5’-
ATACTCCAGAACACGGGCAG-3’ Slc7a11-R 5’-AGTTCCACCCAGACTCGAAC-3’ Gclm-F 5’-
GCACAGCGAGGAGCTTC-3’ Gclm-R 5’-GAGCATGCCATGTCAACTG-3’ Ccl3-F 5’- 
GCCAGGTGTCATTTTCCTGACT-3’ Ccl3-R 5’- TCAGGCATTCAGTTCCAGGTC-3’ C1q-F a 5’- 
CAAGGACTGAAGGGCGTGAA-3’ C1q-R 5’- CAAGCGTCATTGGGTTCTGC-3’ C4-F 5’- 
ACAACAAGGGAGACCCCCAG-3’  C4-R 5’-GCTCAGAGAGCCAGAGTCCTA-3’.   
The qPCR cycling programme was 10 min at 95 °C; 40 cycles of 30 s at 95 °C, 30 s at 65 °C (/30 s at 
62.5 °C for C1q and Ccl2 experiment/40 s at 60 °C for Gclm experiment, 62.5 °C) with detection of 
fluorescence, 30 s at 72 °C; 1 cycle (for dissociation curve) of 1 min at 95 °C and 30 s at 55 °C with a 
ramp up to 30 s at 95 °C with continuous detection of fluorescence The C4 experiment was run at 7 min 
at 95 °C initially and then 40 cycles of 10 s at 95 °C, 30 s at 65 °C (/30 s at 60 °C for Ccl3 experiment) 
with detection of fluorescence followed by the dissociation curve. Data was normalised 
to Gapdh expression as reference and expressed as fold change of wild type sham expression. 
Due to the very small volumes of optic tract enriched RNA samples, more variation was present in these 
qPCR experiments. Criteria were therefore defined to exclude samples from qPCR analysis if 
housekeeper gene was detected >3Ct away from the mean or if gene of interest expression was 1.5 
interquartile ranges less than the first quartile, or 1.5 interquartile ranges more than the third quartile for 
each group mean. The Ccl3 experiment therefore had one sample excluded (wild type sham), and the 




Statistical analysis was performed using SPSS (v22, IBM Corp.) or Graphpad Prism (v5, GraphPad 
Software Inc, La Jolla, USA). Data are presented as mean ± SEM. Repeated measures ANOVA was 
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used to analyse radial arm maze data. Statistical analysis was performed on the first and second half of 
the radial arm maze separately because the first half is primarily a learning phase. Two-way ANOVA 
was used to investigate the effect of BCAS surgery and genotype on immunohistochemistry and gene 
expression data. Bonferroni adjustment was used for post hoc analysis. Associations between microglial 
density and white matter pathology were analysed with Pearson’s correlation analysis. Significance was 




















White matter pathology is more extensive in Nrf2 deficient mice compared to wild type mice post-
BCAS 
We previously demonstrated alterations in the intensity of myelin associated glycoprotein (MAG) 
immunostaining in response to chronic cerebral hypoperfusion that are indicative of altered axon-glial 
integrity [11] and associated with alterations in white matter integrity assessed with diffusion tensor 
imaging [10]. To determine if deficiency of Nrf2 exacerbated MAG pathology, the percentage area of 
MAG immunostaining was quantified in key white matter tracts: corpus callosum, internal capsule and 
optic tract (Fig. 1). There was significant white matter disruption in the corpus callosum following 
BCAS (F(1,28)=6.04, p=0.02) with an additional effect of genotype (F(2,28)=4.47, p=0.02), but no 
interaction or significant post hoc effects (Fig. 1.a). There was no significant white matter disruption in 
the internal capsule as a result of BCAS surgery or genotype (F(1,28)=2.99, p=0.09, F(2,28)=1.89, p=0.17 
respectively) (Fig. 1b). Notably in the optic tract, there was prominent white matter disruption post-
BCAS (F(1,28)=35.84, p<0.0001) with a further effect of genotype (F(2,28)=3.96, p=0.03) and a significant 
interaction between the two variables (F(2,28)=3.87, p=0.03) (Fig. 1c). Post hoc analysis found significant 
differences between all BCAS groups and their respective sham controls (WT p=0.04, Nrf2+/- p=0.004, 
Nrf2-/- p<0.001). Furthermore, there was significantly greater white matter disruption in the Nrf2-/- 
BCAS group compared to both Nrf2+/- (p=0.02) and wild type BCAS (p=0.001) (Fig. 1c). Collectively, 
these data show that cerebral hypoperfusion induced by BCAS surgery causes white matter disruption 
in two major white matter tracts and that this disruption is exacerbated in the absence of Nrf2. 
 
The density of microglia/macrophages is increased following BCAS to a greater extent in Nrf2-/- 
mice compared to wild type and Nrf2+/- mice 
We previously reported that deficits in white matter function and pathology following chronic cerebral 
hypoperfusion was associated with increased density of microglia/macrophages [14, 15] Similarly, Nrf2-
/- mice have been reported to have an increased number of microglia at baseline [47] and an exacerbated 
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microglial response in disease models such as Parkinson’s disease [47] and Alzheimer’s Disease [39-
41]. Therefore, we next investigated whether deficiency of Nrf2 exacerbated levels of 
microglia/macrophages in response to BCAS using Iba1 immunohistochemistry.  
Microglia/macrophage density was quantified by assessing percentage area of Iba1 immunostaining, 
which is an index of microglial activation [48], in corpus callosum, internal capsule and optic tract (Fig 
2). There was a significant increase in density of microglia post-BCAS in the corpus callosum 
(F(1,28)=7.63, p=0.01) with a further effect of genotype (F(2,28)=4.25, p=0.02) but no interaction (Fig. 
2a). Post hoc analysis identified significantly greater density in the Nrf2-/- BCAS group compared to 
sham controls (p=0.004), and other BCAS groups (Nrf2+/- p=0.005 and wild types p=0.003 respectively) 
(Fig 2a). The effect of BCAS surgery and genotype narrowly missed accepted levels of statistical 
significance in the internal capsule (F(1,26)=3.66, p=0.07, F(2,26)=3.15, p=0.06 respectively) (Fig. 2b). 
However, similar to the white matter disruption, there was a profound microglial response in the optic 
tract post-BCAS (Fig. 2c). There was a significant effect of both BCAS surgery and genotype 
(F(1,26)=61.12, p<0.0001, (F(2,26)=7.21, p=0.003 respectively), and a significant interaction (F(2,26)=5.8, 
p=0.008). Post hoc analysis found significantly greater density of microglia in all BCAS groups 
compared to their sham controls (WT p=0.005, Nrf2+/- p<0.001, Nrf2-/- p<0.001) and in the Nrf2-/- BCAS 
group compared to both Nrf2+/- (p=0.002) and wild type BCAS (p<0.001) (Fig. 2c). These data show 
that cerebral hypoperfusion induced by BCAS surgery causes an increased density of microglia in two 
major white matter tracts which exhibit white matter pathology, and that this increase is exacerbated in 
the absence of Nrf2. 
We previously showed that was a correlation between impaired white matter function and microglial 
numbers after BCAS [14, 15] and others have suggested that aberrant activated microglia aggravate 
white matter injury during chronic hypoperfusion [16]. Therefore we next investigated the association 
between microglial density and white matter disruption by correlating Iba1 and MAG immunostaining 
(Fig. 3). There was a significant positive correlation between microglial density and altered MAG 
disruption in corpus callosum (r=0.85, p<0.0001; Fig 3a),  internal capsule (r=0.78 p<0.0001; Fig 3b) 
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and optic tract (r=0.96 p<0.0001; Fig 3c). This indicates that there is an association between microglial 
activation and white matter pathology following BCAS surgery in WT and Nrf2 deficient mice.  
 
Reactive astrocytes are elevated in the optic tract following BCAS and are unaltered by deficiency 
of Nrf2 
Aged Nrf2 knockout mice display elevated levels of reactive astrocytes in white matter compared with 
wild type aged mice [45]. Similarly, elevated levels of reactive astrocytes are reported with Nrf2 
deficiency in models of Parkinson’s disease [47]) and Alzheimer’s disease [39]. Therefore we  
investigated the effects of Nrf2 deficiency on levels of reactive astrocytes following chronic cerebral 
hypoperfusion by undertaking GFAP immunostaining of white matter tracts (Fig. 4).  BCAS surgery 
did not affect the percentage area of GFAP immunostaining in the corpus callosum or the internal 
capsule (F(1,28)=1.08, p=0.31; F(1,27)=0.30, p=0.59 respectively) (Fig 4a-b). However, there was an effect 
of genotype in the corpus callosum (F(2,28)=3.96, p=0.03) and post hoc analysis found that GFAP 
expression in Nrf2-/- animals was overall higher compared with wild types (p=0.03). This genotype effect 
was not present in the internal capsule (F(2,27)=1.52, p=0.24).  Consistent with the white matter 
disruption and the microglial response, there was a significant effect of BCAS surgery in the optic tract 
(F(1,28)=43.61, p<0.0001), although the effect of genotype narrowly missed accepted levels of statistical 
significance (F(2,28)=3.26, p=0.053) (Fig 4c). Post hoc analysis found significant astrogliosis in all three 
BCAS groups compared to their sham controls (WT p=0.005, Nrf2+/- p<0.001, Nrf2-/- p<0.001).  These 
data show that Nrf2 deficiency but not hypoperfusion exacerbated levels of reactive astrocytes in the 
corpus callosum, whereas cerebral hypoperfusion induced by BCAS surgery causes astrogliosis in the 
optic tract that was not altered with deficiency of Nrf2.   
 
Blood brain barrier breakdown is increased following BCAS to a greater extent in Nrf2-/- mice 
compared to wild type and Nrf2+/- mice 
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We previously showed that BCAS induced blood brain barrier breakdown (BBB), although this occurred 
in the chronic response to surgery (6 months) and was not evident at earlier timepoints (1month) [13]. 
Because Nrf2 deficiency exacerbated white matter pathology and microglial/macrophage levels, we next 
investigated if this induced elevated levels of blood brain barrier breakdown by labelling endogenous 
immunologlobulin G (IgG) within brain tissue, which would normally be excluded by an intact BBB 
[49] (Fig 5). BCAS surgery did not induce blood brain barrier breakdown in the corpus callosum (Fig 
5a) (F(2,28)=0.24, p=0.068), which contained negligible levels of IgG immunostaining that were not 
altered by Nrf2 deficiency (F(2,28)=0.24, =0.79). In contrast, in the internal capsule (Fig 5b), there was a 
significant increase in IgG levels with BCAS surgery (F(1,28)=8.99, p=0.006), an effect of genotype 
(F(2,28)=4.9, p=0.015) and a significant interaction (F(2,26)=4.8, p=0.016).  Post hoc analysis found a 
significantly greater density of IgG in the Nrf2-/- BCAS group compared to its sham control (p<0.05) 
and in the Nrf2-/- BCAS group compared to both Nrf2+/- (p<0.05) and wild type BCAS (p<0.01) (Fig 
5b). BCAS surgery also caused a significant elevation in IgG levels in the optic tract (Fig 5c) 
(F(1,28)=6.02, p=0.02), although there was no effect of genotype (F(2,28)=2.2, p=0.13). Post hoc analysis 
found a significant increase in IgG levels in the Nrf2-/- BCAS group compared to its sham control 
(p<0.05). Collectively, these data show that BCAS surgery causes blood brain barrier breakdown in the 
internal capsule and optic tract, an effect that is exacerbated with deficiency of Nrf2.  
 
Nrf2 and Nrf2-related antioxidant genes are unaltered post-BCAS  
To confirm that Nrf2 levels were reduced in Nrf2 deficient mice, and to determine if BCAS surgery 
altered Nrf2 levels in the experimental groups, quantitative PCR analysis was used to assess gene 
expression levels (Fig 6). Optic tract-enriched samples were used, as this was the area with most 
prominent pathology. As expected, Nrf2 levels were significantly reduced to about 50% in Nrf2+/- mice 
(p<0.001) and nearly undetectable in Nrf2-/- compared to wild type mice (p<0.001) (genotype effect; 
F(2,28)=29.6, p<0.0001) (Fig. 6a). However, BCAS surgery did not alter the expression of Nrf2 in either 
WT or Nrf2 deficient mice (F(1,28)=0.01, p=0.91). To further investigate the effect of BCAS surgery on 
Nrf2-mediated signalling, two genes regulated by Nrf2-signalling that are involved in glutathione 
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synthesis were investigated,  Slc7a11 (xCT; encoding the glutamate/cystine antiporter) and Gclm, 
(glutamate-cysteine ligase enzyme subunit) that were previously reported to play a role in Nrf2-mediated 
neuroprotection against ischaemia and hypoxia [30, 31, 50]. However, there was no effect of BCAS 
surgery or genotype on  Slc7a11 levels (F(1,27)=0.23, p=0.63, F(1,27)=2.25, p=0.13 respectively) or Gclm 
expression (F(1,27)=0.39, p=0.54, F(1,27)=0.24 p=0.79 respectively) (Fig 6 b-c). Collectively, these results 
suggest that Nrf2 was reduced as expected in Nrf2 deficient mice, but Nrf2 and Nrf2-regulated genes 
(Slc7a11 and Gclm) were not altered in wild type or Nrf2 deficient mice in response to BCAS.  
Therefore to further investigate alternative mechanisms that may be responsible for the elevated white 
matter pathology in Nrf2 deficient mice in response to BCAS, we investigated levels of 3 pro-
inflammatory genes, complement component C4 and C1q and chemokine ligand 3 (Ccl3) that we 
previously found to be elevated in response to hypoperfusion [9, 15]. The expression of Ccl3 and C1q 
was increased post-BCAS (F(1,28)=7.96, p=0.009, F(1,28)=4.61, p=0.04 respectively), whereas the effect 
of BCAS surgery on C4 expression narrowly missed accepted levels of statistical significance 
(F(1,28)=3.9, p=0.058) (Fig.6 d-f). However, there was no significant effect of genotype for these 3 genes 
(Ccl3-F(2,28)=0.68, p=0.52, C1q-F(2,28)=0.28, p=0.76, C4-F(2,28)=0.48, p=0.63), although post hoc 
analysis identified significantly increased expression of Ccl3 in the Nrf2-/- BCAS group compared to 
sham controls (p=0.048).  These data show that BCAS surgery caused modest elevations in pro-
inflammatory gene expression that were not altered with Nrf2 deficiency with the exception of the 
chemokine ligand C3, that  was further elevated in Nrf2-/- mice following BCAS.  
 
Behaviour assessed with radial arm maze is impaired post-BCAS but is not exacerbated by 
deficiency of Nrf2 
We previously showed that chronic cerebral hypoperfusion caused an impairment in behavioural 
perfomance assessed with an 8-arm radial arm maze, due to the disruption of frontocortical circuity [11], 
and furthermore, boosting Nrf2 signalling specifically in astrocytes caused less pronounced behavioural 
impairments [36]. Since white matter pathology is exacerbated in Nrf2 deficient mice, the next aim was 
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to determine if this was associated with more severe behavioural impairment. There was a significant 
effect of trial during both the first and second half of the test (F(1,84)=7.03, p<0.0001, F(3,84)=3.62, p=0.02 
respectively) indicating that mice were able to learn the task successfully (Fig. 7). The effect of BCAS 
surgery was not significant during the first half of the test (F(1,28)=0.10, p=0.76) but was significant 
during the second half (F(1,28)=4.21, p=0.049) (Fig 5). This indicates that while both sham and BCAS 
groups were learning the task initially, the BCAS groups’ learning plateaus and they commit 
significantly more revisiting errors than sham groups during the second half of the test, indicating that 
BCAS caused significantly more revisiting errors. However, there was no effect of genotype on spatial 
working memory (first half, F(1,28)=0.07, p=0.79; second half, F(1,28)=0.001, p=0.98) (Fig. 7), which 
contests the hypothesis that reductions in Nrf2 exacerbates the behavioural impairment caused by 
















In the current study, we demonstrated that deficiency of Nrf2 resulted in exacerbated white matter 
pathology in response to chronic hypoperfusion, an effect that was most marked with complete absence 
of Nrf2. Furthermore, this was associated with elevated levels of microgliosis and paralleled by elevated 
levels of blood brain barrier breakdown. Although Nrf2-related antioxidant gene expression was not 
altered by chronic cerebral hypoperfusion, there was evidence for elevated pro-inflammatory related 
gene expression following hypoperfusion that was not affected by Nrf2 deficiency.  However, despite 
these molecular and pathological alterations post-BCAS in Nrf2 deficient mice, there was no worsening 
of the behavioural impairment of mice in the radial arm maze.  
 
We found elevated levels of white matter disruption in the present study in the corpus callosum and 
optic tract 6 weeks after chronic hypoperfusion, evident by increased density of MAG positive debris. 
MAG is expressed at the axon-glial interface and is sensitive to hypoxia-induced injury (Aboul-Enein 
et al., 2003). Human post mortem studies identify loss of MAG, in particular its ratio to the more stable 
proteolipid protein (PLP), as a measure of white matter ischaemia [51]. Our previous work showed that 
chronic cerebral hypoperfusion in mice induces alterations to MAG as early as 3 days post-surgery, and 
at least initially in the absence of damage using other markers of myelin such as myelin basic protein 
and Fluoromyelin [9, 12], consistent with hypoxia-induced white matter injury in humans [52].  In 
contrast to our previous work and that of others [9, 11, 53] the optic tract was most severely damaged 
after BCAS whereas the corpus callosum and internal capsule were minimally damaged. However, this 
is consistent with the pattern of damage we recently reported in mice that overexpress Nrf2 specifically 
in astrocytes [36]. The background strain of the mice may account for these differences, as we report 
diffuse damage to multiple white matter tracts using mice on a pure C57Bl6/J background, whereas the 
severe optic tract damage was reported using mice originating from mixed backgrounds (129X1/SvJ or 
FVB/C57Bl6/J F1 mice). These strains may have a different circle of Willis patency, and therefore 
different spatial distribution and severity of hypoperfusion [54]. In addition, we cannot discount that the 
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heightened vulnerability of the optic tract may account for the impaired behaviour in the radial arm maze 
in the hypoperfused mice.   
 
The MAG debris induced by cerebral hypoperfusion, indicative of altered axon-glial integrity, was 
exacerbated in the absence of Nrf2 in the corpus callosum and optic tract. This is consistent with earlier 
studies investigating the role of Nrf2 in the maintenance of white matter integrity in health and disease 
[44, 55]. Hubbs et al. [45] found that the absence of Nrf2 in aged mice (>10 months) is associated with 
vacuolar leukoenephalopathy causing white matter degeneration and myelin-specific oxidative injury. 
Furthermore, patients with de novo missense mutations in NFE2L2 that lead to accumulation of Nrf2 
and increased expression of Nrf2-related genes present with leukoencephalopathy and diminished 
myelin content [56]. Therefore, it would appear that not only lack of Nrf2 but also chronic activation 
may cause pathology in white matter, highlighting the importance of the elaborate mechanisms that 
control Nrf2 activity. 
 
White matter disruption after BCAS has previously been shown to be paralleled by cellular inflammation 
primarily characterised by a microglial response [9, 53, 57, 58], and here we report correlations between 
white matter damage and microglial activation. White matter inflammation is proposed to contribute to 
age and disease-related white matter pathology through excessive pro-inflammatory signalling, 
phagocytosis and oxidative stress [59]. The data presented in the current study are consistent with 
previous work displaying increased density of microglia/macrophages in the corpus callosum, 
correlating with the severity of white matter functional deficit [15]. The results also demonstrate that 
hypoperfusion-induced increases in microglial/macrophage density are further increased in the absence 
of Nrf2, suggesting that signalling through Nrf2 normally acts to limit upregulation of microglia 




Microglia in white matter are important for myelin repair both through phagocytosis of myelin 
degradation products which are neurotoxic and prevent recovery if not cleared [52], and through release 
of growth factors [60]. A study of peripheral nerve crush injury found that Nrf2-/- mice had a reduced 
ability to clear myelin debris [43]. Similarly, Rojo et al. (2010) [47] identified reduced levels of 
phagocytosis in Nrf2-/- mice, suggesting a mechanism by which white matter disruption may be 
exacerbated in Nrf2-/- mice in the current study. Nrf2 has been suggested to act as a regulator of 
microglial dynamics [47, 61].  
 
In the present study we showed differential effects of hypoperfusion and Nrf2 deficiency on reactive 
astrocyte density in white matter, depending on the anatomical area analysed. Interestingly, there was 
an increase in the density of GFAP positive astrocytes in both sham and hypoperfused Nrf2-/- mice in 
the corpus callosum. This finding is in agreement with Hubbs et al. (2007)[45] who found that aged 
Nrf2-/- mice display widespread astrogliosis in white matter including corpus callosum. 
 
Although levels of reactive astrocytes in the optic tract were elevated in response to chronic 
hypoperfusion, their levels were not altered by Nrf2 deficiency. In contrast, chronic hypoperfusion did 
not alter levels of reactive astrocytes in the corpus callosum or internal capsule, despite elevated levels 
of white matter damage and microglia/macrophage in the corpus callosum that were further increased 
in Nrf2 knockout mice. Similarly, in a cuprizone model of demyelination, loss of myelin was 
exacerbated in Nrf2 deficient mice and although this was associated with increased 
microglia/macrophage levels, there was a 50% reduction in levels of reactive astrocytes when compared 
with wild type cuprizone treated mice. Importantly, alterations to levels of reactive astrocytes, as 
assessed with GFAP immunostaining, does not inform on the antioxidant and pro/anti-inflammatory 
capacity of those astrocytes, which may differ between genotypes. Transcriptomic analysis of isolated 
astrocytes display a different profile based on the activating insult, suggested to indicate the functional 
phenotype of that population of reactive astrocytes [62]. Additionally, astrocytes have also been shown 
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to display both regional and age-dependent heterogeneity [63, 64].  Therefore, RNA sequencing of 
isolated astrocytes from different white matter regions would provide more comprehensive information 
about phenotype alterations to astrocytes with chronic hypoperfusion and Nrf2 deficiency. 
 
As expected, the present study showed that there was a 50% reduction of Nrf2 in Nrf2+/- mice and Nrf2 
expression was nearly undetectable in Nrf2-/- mice compared to wild type controls. However, cerebral 
hypoperfusion did not alter the expression of Nrf2 in Nrf2+/- or wild type mice.  The glutathione system 
has been shown to be a major pathway mediating neuroprotection against oxidative stress by Nrf2 [50]. 
However, we did not report any alterations in Slc7a11 and Gclm, genes required for the synthesis of 
glutathione, with either cerebral hypoperfusion or Nrf2 deficiency. It is possible that Nrf2 and Nrf2-
related gene expression may have increased acutely following the reduction of CBF. This is observed 
following middle cerebral artery occlusion where Nrf2 peaks between 8 hours [65] and 24 hours [66] 
but is reduced again at 72 hours. A similar phenomenon is observed following traumatic brain injury 
[67] and indicates that regulatory mechanisms of the Nrf2 system may prevent it from being chronically 
activated, particularly given the white matter lesions and neurological consequences of chronic Nrf2 
elevation reported in patients with mutations in the gene encoding Nrf2 [56].  
 
Because we did not report alterations in Nrf2 or Nrf2-related gene expression following cerebral 
hypoperfusion in the present study, an alternative explanation is that pro-inflammatory gene expression 
may be altered, consistent with the exacerbated levels of microgliosis that we report with both 
hypoperfusion and Nrf2 deficiency.  Pro-inflammatory gene signalling is exacerbated in Nrf2-/- mice in 
other disease models [47] [42] [44]. Here, we found elevated levels of chemokine Ccl3 and complement 
component C1q following cerebral hypoperfusion, consistent with our previous work [12, 15, 36].  Post-
hoc analysis showed that Ccl3 levels were significantly increased in Nrf2-/- mice in comparison with 
shams.  CCL3 regulates the recruitment of microglia as well as perhipheral monocytes and macrophages 
[68]. We also reported that an Nrf2 activating drug, dimethyl fumarate, dampened levels of CCL3 (MIP-
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1α), an effect paralleled by decreased levels of microglia/macrophage and improved white matter 
function [15]. Hypoperfusion induced a significant increase in C1q, C4 expression just missed accepted 
levels of significance, although there was no genotype effect. Activation of the complement pathway 
has been suggested to potentiate chronic inflammation and neurodegeneration [69].   Interestingly, the 
complement cascade has also been shown to be activated by myelin-associated products [70], suggesting 
that white matter disruption in itself may potentiate inflammatory changes observed following cerebral 
hypoperfusion. 
 
Cerebral hypoperfusion has previously been shown to cause an impairment in spatial working memory 
[11, 53] attributed to disruption of frontal-subcortical circuitry. Consistent with previous reports, the 
current study demonstrated that cerebral hypoperfusion impairs behaviour assessed with the radial arm 
maze in both in wild type and Nrf2 deficient mice. However, contrary to the study hypothesis, Nrf2 
deficiency did not exacerbate revisiting errors despite the exacerbation of white matter damage. This 
contrasts with the protective effects that we demonstrated using the radial arm maze in mice with 
astrocyte-specific overexpression of Nrf2 that underwent cerebral hypoperfusion [36]. One limitation of 
the current study is the limited number of Nrf2-/-, mice due to breeding problems. Therefore, it is possible 
that the study is underpowered to detect exacerbated white matter pathology in more subtly damaged 
white matter tracts that may have impacted on the behavioural performance. There is a very limited 
number of studies investigating cognition in models of CNS disease with Nrf2 deficient mice, with only 
one study [40] reporting an exacerbated of spatial learning and memory deficits and working and 
associative memory deficits in an Nrf2 deficient APP/PS1 mutant model of Alzheimer’s Disease. 
However, different disease mechanisms, anatomical differences in pathology and the older age of the 
mice may account for the increased vulnerability of these mice to cognitive deficits.  
 
It is also possible that in the present study, the exacerbation of white matter damage was of an 
insufficient level to worsen the behavioural alterations detected using the radial arm maze at the 6-week 
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time point. Longer duration of hypoperfusion would be expected to intensify the pathological differences 
between wild type and Nrf2 deficient animals, and a later time point in aged animals may have identified 
functional effects of Nrf2-deficiency. Indeed, with ageing the cerebral blood vessels of Nrf2 deficient 
mice have elevated levels of senescence markers, aging-induced vascular inflammation and blood brain 
barrier leakage [71, 72] and white matter leukoencephalopathy [45]. 
 
Conclusions: To conclude, we have demonstrated that chronic cerebral hypoperfusion induces white 
matter pathology, elevated levels of microglia/macrophages and blood brain barrier breakdown that 
were exacerbated with deficiency of Nrf2, thus confirming a role for Nrf2 in protecting white matter 
from pathology and in microglial dynamics. Reactive astrocytes and pro-inflammatory gene expression 
were increased with cerebral hypoperfusion but were not altered by Nrf2 deficiency. Despite elevated 
levels of white matter pathology, there was no exacerbation of the impaired behavioural performance in 














List of abbreviations: 
AD: Alzheimer’s Disease 
BBB: Blood brain barrier 
BCAS: Bilateral common carotid artery stenosis 
C1q: Complement component 1q 
C4: Complement component 4 
Ccl3: Chemokine ligand 3 
EAE: experimental autoimmune encephalomyelitis 
GFAP: Glial fibrillary acidic protein 
Iba1: Ionised calcium binding adaptor molecule-1  
IgG: Immunoglobulin G 
IL-1β: Interleukin 1-beta 
IL-6: Interleukin 6 
MAG: Myelin associated glycoprotein  
MCP-1: monocyte chemoattractant protein-1 (also called CCL2 = chemokine ligand 2). 
Nrf2: Nuclear factor (erythroid-derived 2)-like 2  
PBS: phosphate buffered saline 
PFA: paraformaldehyde 
ROI: region of interest 
SOD: Superoxide dismutase 
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TNFα: Tumour necrosis factor alpha 
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Figure legends:   
Figure 1: White matter disruption is more extensive in Nrf2 deficient mice following BCAS 
surgery 
 (a) White matter disruption was detected post-BCAS in the corpus callosum, with a significant effect 
of genotype (no post hoc differences). (b) There was no significant alteration in the levels of white matter 
disruption in the internal capsule when comparing experimental groups (c) The optic tract displayed 
prominent white matter disruption post-BCAS with a further effect of genotype, with the Nrf2-/- group 
displaying the most severe disruption. Mean ± SEM. Group size presented in each bar. *p<0.05, 
**p<0.01, ***p<0.001 (* indicates post hoc differences between sham and BCAS), #p<0.05, ##p<0.01 
(# indicates post hoc differences between BCAS groups). (d) Representative images of MAG 
immunostaining in the optic tract. Scale bar 50 µm. 
 
Figure 2: The density of microglia/macrophages is increased after BCAS to a greater extent in 
Nrf2-/- mice 
There was an effect of BCAS surgery and genotype on density of Iba1 in the corpus callosum, with the 
Nrf2-/- BCAS group displaying the highest density. (b) The effect of BCAS and genotype narrowly 
missed accepted levels of statistical significance in the internal capsule. (c) The optic tract displayed an 
increased density of Iba1 post-BCAS, with a further effect of genotype, with the Nrf2-/- BCAS group 
displaying the highest density. Mean±SEM. Group size  presented in each bar. **p<0.01, ***p<0.001 
(* indicates post hoc differences between sham and BCAS), #p<0.05, ##p<0.01, ###p<0.001 (# 
indicates post hoc differences between BCAS groups). (d) Representative images of Iba1 staining in the 




Figure 3: Correlation between microglial activation and white matter pathology following BCAS 
surgery in WT and Nrf2 deficient mice. 
There was a significant positive correlation between levels of Iba1 immunostaining and MAG 
immunostaining in the (a) corpus callosum (b) internal capsule (c) optic tract.  
 
Figure 4: Elevated levels of reactive astrocytes after BCAS that are not exacerbated by deficiency 
of Nrf2. (a) There was a significant effect of genotype on GFAP immunostaining (% area) in the corpus 
callosum but there was no effect of BCAS surgery. (b) % Area of GFAP was unchanged in the internal 
capsule. (c) There was a significant effect of BCAS surgery on % area of GFAP immunostaining in the 
optic tract but the effect of genotype narrowly missed accepted levels of statistical significance. Mean 
± SEM. **p<0.01, ***p<0.001 (* indicates post hoc differences between sham and BCAS), #p<0.05 (# 
indicates post hoc differences between wild type and Nrf2-/-). Group sizes presented in each bar. (d) 
Representative images of GFAP staining in the optic tract. Scale bar 50 µm. 
 
Figure 5: Blood brain barrier breakdown after BCAS is exacerbated by Nrf2 deficiency 
(a) There were no significant alterations in IgG levels in the corpus callosum. (b) There was a significant 
effect of surgery and genotype on IgG levels in the internal capsule, with Nrf2-/- displaying highest 
density of IgG. (** indicates post hoc significant difference between sham and BCAS Nrf2-/- mice, # 
and ## indicates a difference between Nrf2-/- BCAS and wild type and Nrf2+/- BCAS groups respectively)  
(c) There was a significant increase in IgG levels in the optic tract with **BCAS surgery (* indicates 
post hoc significant difference between sham and BCAS Nrf2-/- mice). Mean ± SEM. **p<0.01, 
#p<0.05, ##p<0.01   (d) Representative images of IgG staining in the optic tract, brown stain depicts 






Figure 6: Nrf2, Nrf-2 regulated antioxidant and pro-inflammatory genes in the optic tract after 
BCAS surgery 
(a) There was a significant effect of genotype on Nrf2 expression but no effect of BCAS surgery. Nrf2 
was reduced by ~50% in Nrf2+/- mice and almost undetectable in Nrf2-/- mice. (b) There was no effect 
of BCAS surgery or genotype on Slc7a11 (c) or Gclm expression, (d) however, BCAS surgery increased 
the expression of Ccl3 and (e) C1q. (f) The effect of BCAS surgery just missed accepted levels of 
statistical significance for C4 expression and there was no genotype effect on any gene. Gene expression 
was normalised to Gapdh and expressed as fold change compared to wild type shams. Mean ± SEM. 
Group size presented in each bar. Dashed line indicates WT sham mean. *p<0.05 (* indicates post hoc 
differences between sham and BCAS groups), ##p<0.01, ###p<0.001 (# indicates differences between 
genotypes). 
 
Figure 7: Spatial working memory is impaired after BCAS but is not exacerbated by deficiency 
in Nrf2. 
There was an effect of trial during both first (blocks 1-4)  and second half (blocks 5-8) of the test 
indicating learning over time. During the second half of the test, revisiting errors were significantly 
higher post-BCAS demonstrating impaired spatial working memory. However, there was no effect of 
genotype on revisiting errors during either the first or second part of the test. Post hoc analyses identified 
no further significant differences. Mean ± SEM. *p<0.05 (* indicates main effect of BCAS surgery 
during second half of test). Group sizes are indicated in the graph. 
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